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Abstract
Background: Inborn errors of metabolism (IEMs) are individually rare; however, they are collectively common. More
than 600 human diseases caused by inborn errors of metabolism are now recognized, and this number is
constantly increasing as new concepts and techniques become available for identifying biochemical phenotypes.
The aim of this study was to determine the type and distribution of IEMs in patients presenting to a tertiary care
center in Saudi Arabia. METHOD: We conducted a retrospective review of children diagnosed with IEMs presenting
to the Pediatric Department of King Abdulaziz Medical City in Riyadh, Saudi Arabia over a 13-year period.
Results: Over the 13- year period of this retrospective cohort, the total number of live births reached 110,601. A
total of 187 patients were diagnosed with IEMs, representing a incidence of 169 in 100,000 births (1:591). Of these,
121 patients (64.7 %) were identified to have small molecule diseases and 66 (35.3 %) to have large molecule
diseases. Organic acidemias were the most common small molecule IEMs, while lysosomal storage disorders (LSD)
were the most common large molecule diseases. Sphingolipidosis were the most common LSD.
Conclusion: Our study confirms the previous results of the high rate of IEMs in Saudi Arabia and urges the health
care strategists in the country to devise a long-term strategic plan, including an IEM national registry and a high
school carrier screening program, for the prevention of such disorders. In addition, we identified 43 novel
mutations that were not described previously, which will help in the molecular diagnosis of these disorders.
Keywords: Inborn errors of metabolism, IEMs, Saudi Arabia, Lysosomal, Organic acidemia, Mitochondrial, Fatty acid
oxidation defects
Background
Inborn errors of metabolism (IEMs) are defined as
monogenic diseases that result in dysfunctional proteins
encoded by different genes, which in many cases lead to
loss of activity of the enzymes involved [1]. More than
600 different inborn errors of metabolism have been rec-
ognized up to this point, and this number is constantly
increasing as new concepts and techniques become
available for identifying biochemical phenotypes. IEMs
are extremely heterogeneous making their classification
a primary challenge. Several informal systems of classifi-
cation currently exist. IEMs can be classified according
to the organs involved, such as neurological or hepatic
disorders or according to the organelle involved, such as
mitochondrial, peroxisomal or lysosomal disorders. Dis-
orders can also be classified according to the age of
presentation ranging from neonatal onset to juvenile and
adult onset. Because each of these approaches may de-
pend upon the actual setting, no single classification is
universally applied [2]. One common and informative
classification system involves the classification of IEMs
into small and large molecule disorders [3]. Small
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molecule IEMs have an acute intoxication presentation
with a remitting-relapsing clinical course. These include
organic acidemias, vitamin responsive disorders, urea
cycle disorders, inborn errors of carbohydrates, haem
synthesis defects, cholesterol biosynthesis defects, and
amino acids and metal transport defects. Large molecule
IEMs have a gradual and insidious progressive presenta-
tion. These include glycogen storage disorders, sphingoli-
pidosis, mucopolysaccharidosis, oligosaccharidosis,
mitochondrial disorders and congenital disorders of glyco-
sylation [2]. The diagnosis of IEMs is mainly based on bio-
chemical investigations, which include the screening of
several metabolites in the blood, urine and cerebro-
spinal fluid (CSF); analysis of enzymatic activities, and
molecular genetics testing.
The incidence of such disorders vary from country to
country and from region to region. In one Australian
study the incidence was reported to be 15.7 per 100,000
births whereas, in Italy, the reported incidence was 27
per 100,000 births [4, 5]. In the West Midlands region in
the United Kingdom (UK), the incidence reached up to
1:784 and in British Columbia, Canada, the incidence
was reported to be 1:2500 [6, 7].
These disorders are usually inherited as autosomal
recessive disorders, explaining why IEMs are common in
populations with a high rate of consanguineous mar-
riages, such as Saudi Arabia. In Saudi Arabia, the rate of
consanguineous marriages reaches up to approximately
60 % [8, 9].
Despite the high frequency of IEMs, apart from the
eastern region study [10], only a few anecdotal epi-
demiological studies in Saudi Arabia have discussed the
incidence, type and distribution of such devastating dis-
orders. Most of the remaining reports in the literature
were limited to case reports and case series. In this
study, we report the incidence, type, and distribution of
IEMs presenting to King Abdulaziz Medical City
(KAMC) in the middle region of Saudi Arabia over
13 years. In addition, we identified 43 novel mutations.
Methods
King Abdulaziz Medical City (KAMC) is a tertiary center
in Saudi Arabia, that commenced operations in 1983.
The bed capacity is 715, and an average of 8500 births
per year occur at the center. This medical city passed
the requirements for accreditation under the Joint Com-
mission International (JCI) standards with excellent per-
formance in December 2006. The current study is a
retrospective review of all cases at the Pediatric Depart-
ment of King Abdulaziz Medical City (KAMC) in
Riyadh, Saudi Arabia. The duration of the study was
13 years, from 01-01-2001 to 31-12-2014. All patients
included were born during this period. The cases were
identified according to medical records via diagnostic
codes and the genetic division’s database. The study was
approved by the research committee of King Abdullah
International Medical Research Centre (KAIMRC) in
Riyadh, Saudi Arabia.
The diagnostic algorithm starts by referring patients
based on clinical suspicion to genetic/metabolic facility
from other departments, and from positive new born
screening (NBS) after 2011. All accepted cases undergo
phenotype related screening biochemical investigations.
Confirmation of diagnosis is then achieved either by
measuring enzyme activity and/or by targeted molecular
tests. In case of unrevealing confirmatory investigations
or vague presentation, whole exome or whole genome
sequencing is requested.
The diagnosis of each IEM was based on clinical
and biochemical investigations, including analyses of
ammonia, lactic acid, total homocysteine, plasma
amino acids, the acylcarnitine profile, urine aminoa-
cids, urine for organic acids, copper, ceruloplasmine
levels, very long chain fatty acids, transferrin isoe-
lectrofocusing, carbohydrate-deficient transferrin and
urine for polyols.
DNA molecular genetic testing was performed in com-
mercial clinical international labs including CENTO-
GENE, GeneDx, Emory Genetics, Cincinnati Children’s
Hospital Medical Center, Bioscientia and Nijmegen
Medical Center. All of the parents of the patients with
IEMs were tested for carrier status.
Incidence was calculated by dividing the number of
diagnosed cases by the number of total births during the
study period and multiplying by 100,000 [11].
Results
Over the 13-year period of this retrospective cohort
study, the total number of live births reached 110,601. A
total of 187 patients were diagnosed with an IEM, result-
ing in an incidence of 169 in 100,000 births (1:591). Of
these patients, 121 (64.7 %) were identified to have a
small molecule disease (Table 1) and 66 (35.3 %) to have
a large molecule disease (Table 2). The overall mean,
median and range of age at diagnosis were 3.2 years,
1.2 years and from 1 day to 13 years respectively.
Tables 1 and 2 show the type and distribution of IEMs
from 2001 to 2014 and illustrate the estimated incidence
per 100,000 live births for each group of disorders and
the mean, median and range of age at diagnosis for each
group. The lysosomal storage disorders (LSDs) were the
most common diagnosed group, in general, and were
observed in 39/187 patients (20.8 %). Sphingolipidoses
represent the largest subgroup of the LSDs (22/39;
56.4 %), and GM1 gangliosidosis (infantile phenotype)
was the most prevalent disorder. The second most com-
mon category was organic acidemias (34/187; 18.2 %),
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Table 1 Small-molecule disorders of IEMs in KAMC (2001–2014). Total numbers of live births (110,601)









Organic acidemias 34 30 1.8 years 60 days 1 day–10 years
Propionic acidemia 9 30.2 days 20 days 1 day–6 months
Methylmalonic acidemia 7
Mutase deficiency 5
Cobalamin A defect 1
Cobalamin C defect 1
Glutaric acidemia 3
3-hydroxy-3-methylglutaryl-CoA lyase deficiency 4
3-Methylcrotonylco A carboxylase deficiency 3
Biotinidase deficiency 3





Aminoacidopathies 30 27 3.3 years 10.5 months 1 day–13 years
Homocystinuria 14 7 years 7.5 years
• Classical 11
• MTHFR deficiency 2
• MAT deficiency 1
PKU 5
• Classical 3
• Non-PKU hyperphenylalaninemia 2
Biopterin Synthesis Defect PTPS deficiency 4
MSUD 5
Asparagine synthetase deficiency 2
Vitamins responsive disorders 18 16 5.7 years 5.5 years 6 months–10 years
Biotin Thiamine Responsive Basal Ganglia Disease 17
Pyridoxine-dependent epilepsy 1
Inborn Errors of Carbohydrates 12 11 3.1 years 1.3 years 1 week–7 years
Galactosemia 4
Transaldolase deficiency 6
Hereditary fructose intolerance 1
Fructose 1,6 bisphosphatase deficiency 1
Urea Cycle Disorders 12 11 12 days 7 days 1 day–30 days
Argininosuccinic Aciduria 8
Citrullinemia 4
Fatty Acid Oxidation Defects 5 4 1.4 years 2 days 2 days–7 years
VLCAD deficiency 3 21 days 2 days 2 days–60 days
MCAD deficiency 1 2 days 2 days 2 days
Carnitine uptake defect 1 7 years 7 years 7 years
Aminoacids transport defect 5 4 10 years 11 years 6–13 years
Cystinuria 5
Alfadhel et al. Orphanet Journal of Rare Diseases  (2016) 11:126 Page 3 of 12
with propionic acidemia (PA) as the most common dis-
order in that group. Aminoacidopathies were diagnosed
in 30/187 patients (16 %). Fatty acid oxidation defects
(FAOD) were diagnosed in 5/187 patients (2.7 %), and
the frequency of patients with urea cycle disorders
(UCD) was 12/187 (6.4 %). The most common FAOD
was very long-chain acyl-CoA dehydrogenase deficiency
(VLCAD), while argininosuccinic aciduria was the most
common UCD. Mucopolysaccharidoses (MPS) were di-
agnosed in 15/187 patients (8 %), with MPS VI as the
predominant type. Fourty-three novel mutations were
identified, and missense mutations were the most com-
mon type of mutations (Tables 3 and 4). All the listed
novel mutations fit with the clinical features of the dis-
ease, biochemical biomarkers support genotype pheno-
type correlation and they segregate well within the
patients and family members.
Discussion
In this report, we describe the incidence of IEMs in a sin-
gle tertiary center in the middle region of Saudi Arabia
over more than a decade. We reported an incidence of
1:591 individuals, which is the highest incidence for IEMs
reported to this point. Our study is the second epidemio-
logical report after that of Moammar et al., 2010, who
reported a incidence of 1:667 [10]. If we combine the two
studies, the cumulative incidence is 1:635 births or 157
per 100,000, which is still one of highest reported inci-
dence rates across the world. KAMC is one of the largest
medical institutions in the Kingdom and is also a referral
center; therefore to obtain a more accurate estimation of
incidence of these disorders we have excluded the 69
patients who were diagnosed with IEM but not born at
KAMC. If we combine the referred cases with those of
patients born at the hospital, we obtain an incidence of
231.5 in 100,000 births (1:432).
Our study confirms the conclusions drawn by Moam-
mar et al., 2010, LSDs are the most commonly identified
group of disorders and organic acidemias are the most
prevalent small molecule diseases. Our work also sup-
ports the notion that MPS VI is the most common type
of mucopolysaccharidosis in Saudi Arabia. The results
also support the wide variation in incidence of genetic
diseases between Saudi Arabia and other parts of the
world [12]. In our study for example the recorded num-
ber of PTPS exceeds the classical PKU which is reverse
in Caucasian population [13]. This is more evident in
PA, in which incidence in Saudi Arabia far exceeds the
global incidence [14]. During the course of our study we
discovered 9 new PA cases in our center, with incidence
of 1 per 12,500 live births.
Our study showed unique phenotypes in comparison
with the literature. Our three VLCAD patients for ex-
ample had early presentation with severe phenotype
ended with early death. Their genotype mutations were
one novel missense mutation in exon 6, c.494 T > C
(p.Phe165Ser) and the other two had previously re-
ported nonsense mutation in exon 2, c.65C > A
(p.Ser22*). Although these mutations are not clear null
mutations [15], they resulted in severe phenotype. Al-
ternatively, the most common phenotype in VLCAD is
the milder late onset with the missense mutation
p.Val283Ala being the most prevalent disease causing
variant [15]. This reflect the poor genotype-phenotype
correlation.
In this study the number of private mutations was al-
most double that of founder mutations, which support
the previous report of Al-Owain et.al (2012) who noted
that private mutations outweigh founder mutations in
Saudi Arabia [12].
Interestingly, among the diseases discovered by our
study, 35 diseases are amenable for treatment. Recent
advances in early diagnostic tools like the expanded New
Born Screening program list, which can detect 14 of the
listed diseases, and the availability of treatment options
like enzyme replacement therapy, opened new horizons
for these patients and their families.
With the implementation of next generation sequen-
cing (WES and WGS) we were able to solve many ob-
scure cases. Additionally, new diseases and new variants
might be discovered more easily. It is possible to see
NGS a first line diagnostic tool in the near future.
Table 1 Small-molecule disorders of IEMs in KAMC (2001–2014). Total numbers of live births (110,601) (Continued)
Metal transport defect 2 2 8.5 years 8.5 years 7–10 years
Wilson disease 2
Disorders of Haem biosynthesis 2 2 12.5 years 12.5 years 12–13 years
Acute intermittent porphyria 2
Cholesterol biosynthesis defect 1 1 1 year 1 year 1 year
CHILD syndrome 1
Total 121 109 3.3 years 9 months 1 day–13 years
MTHFR methylenetetrahydrofolatereductase, MAT methionine adenosyltransferase, PKU phenylketonuria, MSUD maple syrup urine disease, VLCAD very long-chain
acyl-CoA dehydrogenase, MCAD medium-chain acyl-CoA dehydrogenase, CHILD Congenital hemidysplasia with ichthyosiform erythroderma and limb defects, PTPS
6-Pyruvoyl-Tetrahydropterin Synthase
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Table 2 Large-molecule disorders of IEMs in KAMC (2001–2014). Total numbers of live births (110,601)









Lysosomal Storage Diseases (LSD) 41 37 3.6 year 3 years 2 months–13 years
Sphingolipidosis 22 20 3.1 years 2 years 2 months–13 years
Fabry disease 3
Sandhoff disease 2
Niemann–Pick disease type B 1
Niemann–Pick disease type C 3
GM1 gangliosidosis (infantile phenotype) 4
Metachromatic leukodystrophy 3
Saposin B Deficiency 2
Krabbe disease 1










Neuronal ceroid-lipofuscinoses 3: 2 type 6, and 1 type 8 5.3 5 5–6 years
GSD II 2 3.1 months 3.1 months 1 week to 6 months




Mitochondrial disorders 12 11 2.2 years 8 months 1 week–8 years
Leigh disease 3
Pyruvate dehydrogenase deficiency 2
Pyruvate carboxylase deficiency 2
Mitochondrial DNA depletion syndrome 3 1
Mitochondrial DNA depletion syndrome 5 1
Cardioencephalomyopathy, fatal infantile,
due to cytochrome c oxidase deficiency 1
1
3-Methylglutaconic aciduria with deafness,
encephalopathy, and Leigh-like
1
Primary Coenzyme Q10 deficiency type 5 1
Peroxisomal disorders 7 6 2 years 9 months 1 week–8 years
Primary hyperoxaluria type 1 5
Zellweger syndrome 1
Rhizomelic Chondrodysplasia Punctata 1
Congenital disorders of glycosylation (CDG) 1 (CDG 1 L) 1 8 years 8 years 8 years
Total 66 60 3.1 years 2 years 1 week–13 years
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Table 3 Mutations for small molecule IEMs
Disease category Disease Gene Reported mutations Novel mutations Founder Vs.
Private
Type of mutation
Organic acidemias Propionic acidemia PCCA c.425G > A(p. Gly142Asp) Founder Homozygous, missense
c.350G > A (p.Gly117Asp) Private
PCCB c.1050dupT Private Dupplication
Methylmalonic acidemia MUT c.329 A > G(p. Tyr110Cys) Founder Homozygous, missense,
c.1677-1G > C Private Splice
Cobalamin A Defect MMAA c.586C > T (p.Arg196*) Private Nonsense
Cobalamin C defect MMACHC c.394C > T (p. Arg132*) Private Nonsense
Glutaric acidemia GCDH c.1144G > A (p.Ala382Thr) Private missense
c.853-2A > G (IVS8-2A > G) Private Splice
c.278A > G (p.His93Arg) Private missense
3-hydroxy-3-methylglutaryl-CoA lyase
deficiency
HMGCL c.122G > A Founder missense
3-Methylcrotonyl CoA carboxylase
deficiency
MCCC1 c.1808 dup A(p. p.Asn603
Lysfs*5)
Private Homozygous, duplication
MCCC2 c.1147A > T (p.Lys383*) Private Nonsense
Biotinidase deficiency BTD c.755A > G (p.Asp252Gly)
c.1330G > C (p.Asp444His)
Private Two heterozygous missense
mutations in Exon 4
3-Methylglutaconic aciduria type III OPA3 c.194delG(p. Gly65Alafs*7) Private Homozygous, deletion
Ethylmalonic encephalopathy ETHE1 c.263 C > T(p. Ser88Leu) Private Homozygous, missense
B-Ketothiolase deficiency ACAT1 c.412-419del(p.
Gln138Tyrfs*36)
Private Homozygous, deletion
Isovaleric acidemia IVD c.358C > T(p. Arg120X) Private Homozygous, nonsense




Classical CBS c.969G > A (p.Trp323Ter) Founder Homozygous missense
c.1006C > T (p.Arg336Cys) Founder Homozygous missense
MTHFR deficiency MTHFR c.680C > T (p.Thr227Met) Private
MAT deficiency MAT1A c.1081G > T(p.Val361Phe) Private Homozygous, missense
PKU PAH c.1169A > G (p.Glu390Gly) Private Homozygous, missense
PTPS deficiency PTPS c.238A > G(p. Met80Val) Founder Homozygous, missense
c.169_171delGTG (p.Val57del) Founder Homozygous, deletion
MSUD BCKDHA c.347A > G(p. Asp116Gly) Private missense














Table 3 Mutations for small molecule IEMs (Continued)
BCKDHB c.674 T > C(p.Leu225Pro) Private missense
c.1144 T > C(p.Cys382Arg) Private Homozygous, missense
Asparagine synthetase deficiency ASNS c.1160A > G (p.Tyr377Cys) Founder Homozygous, missense
Vitamins responsive
disorders
Biotin Thiamine Responsive Basal Ganglia
Disease
SLC19A3 c.1264A > G (p.Thr422Ala) Founder Homozygous, missense
Pyridoxine-dependent epilepsy ALDH7A1 c.877dupAA (p.Ser293Lysfs*22) Private Duplication
Inborn Errors of
Carbohydrates
Galactosemia GALT c.691 C > T (p.Arg231Cys) Founder Homozygous, missense
c.404C > T (p.Ser135Leu) Private Homozygous, missense
c.563A > G (P.Gln188Arg) Private Homozygous, missense
Transaldolase Deficiency TALDO1 c.793delC (p.Gln265ArgfsX56) Founder Deletion
Hereditary fructose intolerance ALDOB c.360_363delCAAA
(p.Asn119LysfsX31)
Private Deletion
Fructose 1,6 bisphosphatase deficiency FBP1 c.114_119dup (p.
Cys39_Thr40dup)
Private Duplication
Urea cycle disorders Argininosuccinic Aciduria ASL c.556C > T (p.Arg186Trp) Founder Missense
c.1060C > T (p.Q354X) Founder Nonsense
Citrullinemia type 1 ASS1 c.364-2A > G Founder Homozygous, intronic
c.370G > A (p.Asp124Asn) Founder Homozygous, missense
Fatty acid oxidation defect VLCAD ACADVL c.494 T > C(Phe165Ser) Private Homozygous, missense
VLCAD ACADVL c.65C > A (p.Ser22*) Founder Nonsense
MCAD ACADM c.255 G > T(p.Gly119*);) Private Homozygous, nonsense
c.938 T > G(p.Phe313Cys Private Homozygous, missense
Carnitine uptake defect SLC22A5 c.1385G > A(p. Gly462Asp) Private Homozygous, missense
Aminoacids transport
defect
Cystinuria SLC3A1 c.1711 T > A(p.Cys571Ser) Founder Homozygous, missense
c.1400 T > A (p.Met467Lys) Private
SLC7A9 c.1166 C > T(p.Thr389Met) Private Homozygous, missense
Metal Transport Defect Wilson disease ATP7B c.2230 T > C (p.Ser744Pro) Founder Homozygous, missense
Disorders od Haem
biosynthesis
Acute Intermittent Poephyria HMBS c.760delC (p.Leu254X) Founder Nonsense
Cholesterol biosynthesis
defect
CHILD syndrome NSDHL c.314C > T (p.Ala105Val) Private Homozygous, missense














Table 4 Mutations for large molecule IEMs
Disease category Disease Gene Reported mutations Novel mutations Founder Vs.
Private
Type of mutation
LSD Sphingolipidosis Fabry GLA c. 782G > T (p.Gly261Val) Founder Homozygous,
missense
Sandhoff disease HEXB c.1169 + 3_1169 + 10delAAGTTGTT
(p.Gly65 AlafsX7)
Private Deletion
Niemann-Pick disease type B SMPD1 c.1267 C > T (p.His423Tyr) Founder Homozygous,
missense
Niemann-Pick disease type C NPC1 c.2130 + 1G > A; Founder Homozygous,
intronic
c.2443_2444delp.ser815Leufs*54 Private deletion
GM1 gangliosidosis GLB1 c.950G > A(p. Trp317*) Private Homozygous,
nonsense
c.171C > G (p.Tyr57X) Founder Homozygous,
missense
Metachromatic leukodystrophy ARSA c.1108-2A > G Private Homozygous,
intronic
Saposin B deficiency PSAP c.722G > C (p.Cys241Ser Founder Homozygous,
missense




MPSI IDUA c.1868 T > C(p. Leu623Pro) Private Homozygous,
missense
MPSII IDS c.405A > C(p. Lys135Asn) Private Homozygous,
missense
MPSIIIA SGSH c.664-13C > G Private Homozygous,
intronic
c.535G > A (p.Asp179Asn) Private Homozygous,
missense
MPS IVA GALNS c.120 + 1G > C (IVS1 + 1G > C) Private Homozygous,
missense
c.860C > T (p.Ser287Leu) Private Homozygous,
missense
c.697G > A (p.Asp233Asn) Private Homozygous,
missense
MPSVI ARSB c.753C > G (p.Tyr251*) Founder Homozygous,
nonsense
c.430A > G (p.His393ARG) Founder Homozygous,
missense















Table 4 Mutations for large molecule IEMs (Continued)




α-mannosidosis MAN2B1 c.1340A > T (p.Asp447Val) Private Homozygous,
missense








GSDII GAA c.1431delT(p. lle477fs) Private Homozygous,
deletion
c.1657C > T(p. Gln553*) Private Homozygous
nonsense
Glycogen storage disease GSDIII AGL c.4353G > T(p. Trp1451Cys); Private Homozygous,
missense
GSDIV GBE1 c.998A > T (p.Glu 333 Val) Private Homozygous,
missense
GSD IX PHKG2 c.130C > T (p.Arg44*) Founder Homozygous
nonsense
PHKB Deletion Exon 5 and 6 Private Homozygous,
deletion
Mitochondrial disorders Leigh disease MTATP6 m.8993 T > G (p.Leu156Arg) Private Homoplasmic,
missense
COX15 c.649C > T (p.Arg217Trp) Private Homozygous,
missense




PDHA1 c.1132C > T (p.Arg378Cys) Private Hemizygous
missense
Pyruvate Carboxylase Deficiency PC c.3116_3126del (p.Leu1039Glnfs*7) Private Deletion
Mitochondrial DNA depletion syndrome 3 DGUOK c. 617G > A (p. R206k) Private Homozygous,
missense
Mitochondrial DNA depletion syndrome 5 SUCLA2 c.362_363del (p.Ile121Serfs*38) Private Deletion
Cardioencephalomyopathy, fatal infantile, due to
cytochrome c oxidase deficiency 1
SCO2 c.2 T > C(p.Met1?) Private Homozygous,
missense
3-Methylglutaconic aciduria with deafness,
encephalopathy, and Leigh-like
SERAC1 c.438del (p.Thr147Argfs*22) Private Deletion















Table 4 Mutations for large molecule IEMs (Continued)
Peroxisomal disorders Primary hyperoxaluria type 1 AGXT c.187G > C (p.Gly63Arg) Founder Homozygous,
missense
Zellweger syndrome PEX5 c.1578 T > G (p.Asn526Lys) Private Homozygous,
missense



















The markedly high numbers of metabolic diseases in
Saudi Arabia in general and in our center in particular,
with mostly homogenous genotypes, paves the way for
future collaboration with international parties, research
centers and drug industry, to help providing treatment
for our patients. This environment is ideal for wide
spectrum of clinical trials of various phases, to speed up
the process of new medications discovery.
The limitations of the presented cohort study are clear.
These include the fact that the study is confined to a sin-
gle center in one particular region and contains a small
sample size; therefore, the internal and external validity
of the study is threatened. Such a retrospective review
increases the risk of selection and information biases.
Therefore, the numbers mentioned in this study should
be taken with caution until further larger studies con-
firm or refute such findings. The retrospective nature
risks missing cases due to poor documentation. In
addition, some patients with metabolic disorders may
not be seen at the medical center due to early death
prior metabolic intervention. In addition, cases with a
relatively mild disease may never have presented to the
specialized metabolic center, which also contributes to
the bias inherent in this study. The variability in ages at
diagnosis is attributed to the delay in referring cases to
the metabolic facility from other departments, and these
numbers should not reflect the expected age of presenta-
tion for the listed diseases.
The incredibly high rate of IEMs in Saudi Arabia com-
pels the health care administration in the country to
develop a long-term strategic plan for the prevention of
such disorders. First, a national registry should be imple-
mented, and through that registry, a determination of
the most common IEM and most common mutations in
the population can be made. Second, genetic screening
of high school students by DNA molecular testing
should be performed to identify carriers for the most
common disorders in the Saudi population. Premarital
molecular screening can help couples, who carry the
same disease causing variants, to take informed decision
regarding their marriage and the consequences of their
decision. Such a strategy has proven to be effective in
another population [16]. Finally, intensive educational
campaigns aimed at the community through schools,
TV, and web-based social media should be initiated.
Conclusion
In this study, we report the incidence, type, and distribu-
tion of IEMs presenting to King Abdulaziz Medical City
(KAMC) in the middle region of Saudi Arabia over
13 years. We also identified 43 novel mutations in 37
genes. Our study emphasizes the high incidence of IEMs
in the Saudi population and urges the health care ad-
ministration in the country to develop a long-term
strategic plan for the prevention of such disorders,
including an IEMs national registry and a high school
carrier screening program.
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